Variant: NM_000261.2(MYOC):c.1091G>T (p.Gly364Val)

Version: 2.0
JSON-LD PDF

CA119170

7947 (ClinVar)

Gene: MYOC (HGNC:4653)

Condition: open-angle glaucoma

Inheritance Mode: Autosomal dominant inheritance

UUID: 30a3432f-835c-4e0b-942a-7a84d0c5f07c

Approved on: 2026-01-21

Published on: 2026-01-20

HGVS expressions

NM_000261.2:c.1091G>T
NM_000261.2(MYOC):c.1091G>T (p.Gly364Val)
NC_000001.11:g.171636349C>A
CM000663.2:g.171636349C>A
NC_000001.10:g.171605489C>A
CM000663.1:g.171605489C>A
NC_000001.9:g.169872112C>A
NG_008859.1:g.21285G>T
ENST00000037502.11:c.1091G>T
ENST00000637303.1:c.235-2281C>A
ENST00000638471.1:c.*429G>T
ENST00000037502.10:c.1091G>T
ENST00000614688.1:c.*55G>T
NM_000261.1:c.1091G>T

Pathogenic

• Met criteria codes: PS3_Moderate PS4_Supporting PP1_Strong PM2_Supporting PP3_Moderate

• Not Met criteria codes: BS3 BS1 BP4 BP7 PS2 PS1 BA1 PM5 PM4

Expert Panel

Glaucoma VCEP

Criteria Specification Information

Criteria Specification: ClinGen Glaucoma Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for MYOC Version 2.0.0

Evidence submitted by expert panel

Glaucoma VCEP

The c.1091G>T variant in MYOC is a missense variant predicted to cause substitution of Glycine by Valine at amino acid 364 (p.Gly364Val). This variant was not found in any genetic ancestry group of gnomAD (v4.1.0), meeting the ≤ 0.0001 threshold set for PM2_Supporting in a genetic ancestry group of at least 10,000 alleles. The REVEL score = 0.896, which was within the 0.773-0.931 range for PP3_Moderate, predicting a damaging effect on MYOC function. The Gly364Val protein had increased instability and reduced secretion levels compared to wild type myocilin protein in these studies (PMIDs: 16466712, 21612213, 23129764). The assays met the OddsPath threshold for PS3_Moderate (> 4.3), indicating that this variant did impact protein function. This protein has also been assessed in these other studies (PMIDs: 10545602, 11152659, 15069026, 16297911), however, the same level of evidence was not met. 18 segregations in 2 families, with juvenile or primary open angle glaucoma (JOAG or POAG), have been reported (PMID: 9535666), which fulfilled PP1_Strong (≥7 meioses in >1 family). 2 probands with JOAG or POAG have been reported carrying this variant (PMID: 10196380), which met PS4_Supporting (≥ 2 probands). In summary, this variant met the criteria to receive a score of 10 and to be classified as pathogenic (pathogenic classification ≥ 10, adapted from PMID: 32720330) for juvenile open angle glaucoma based on the ACMG/AMP criteria met, as specified by the ClinGen Glaucoma VCEP (v2.0.0, 5 Dec 2024): PP1_Strong, PS3_Moderate, PP3_Moderate, PS4_Supporting, PM2_Supporting.

Met criteria codes

• PS3_Moderate: The Gly364Val protein had increased instability and reduced secretion levels compared to wild type myocilin protein in these studies (PMIDs: 16466712, 21612213, 23129764). The assays met the OddsPath threshold for PS3_Moderate (> 4.3), indicating that this variant did impact protein function. This protein has also been assessed in these other studies (PMIDs: 10545602, 11152659, 15069026, 16297911), however, the same level of evidence was not met.
• PS4_Supporting: 2 probands with JOAG or POAG have been reported carrying this variant (PMID: 10196380), which met PS4_Supporting (≥ 2 probands).
• PP1_Strong: 18 segregations in 2 families, with juvenile or primary open angle glaucoma (JOAG or POAG), have been reported (PMID: 9535666), which fulfilled PP1_Strong (≥7 meioses in >1 family).
• PM2_Supporting: This variant was not found in any genetic ancestry group of gnomAD (v4.1.0), meeting the ≤ 0.0001 threshold set for PM2_Supporting in a genetic ancestry group of at least 10,000 alleles.
• PP3_Moderate: The REVEL score = 0.896, which was within the 0.773-0.931 range for PP3_Moderate, predicting a damaging effect on MYOC function.

Not Met criteria codes

• BS3: This criterion was not met as PS3_Moderate has been met.
• BS1: This criterion was not met as PM2_Supporting has been met.
• BP4: This criterion was not met as PP3_Moderate has been met.
• BP7: This criterion did not apply to this variant.
• PS2: This variant has not been identified de novo.
• PS1: An established LP or P variant causing this same amino acid change has not been identified.
• BA1: This criterion was not met as PM2_Supporting has been met.
• PM5: No other LP or P missense variants at this amino acid residue have been identified.
• PM4: This criterion did not apply to this variant.